Cover Image
Market Research Report

RNA Technologies Enabling Drug Discovery and Development

Published by Frost & Sullivan Product code 763648
Published Content info 50 Pages
Delivery time: 1-2 business days
Price
Back to Top
RNA Technologies Enabling Drug Discovery and Development
Published: December 28, 2018 Content info: 50 Pages
Description

Redefining the Future of Healthcare through Groundbreaking RNA Therapies

This research service encompasses a comprehensive analysis of RNA therapy industry from the following perspectives:

  • Industry Drivers and Challenges
  • Technology Snapshot and Trends
  • Clinical Pipeline Analysis
  • Overview of the IP Landscape
  • Innovator Profiles
  • Future Roadmap

The RNA therapy platforms covered include:

  • Splice-Switching Oligonucletides (SSO)
  • Other Anti-Sense Oligonucleotide (ASO)
  • Aptamers
  • RNA-interference
  • mRNA
  • saRNA

An appendix is included, comprising lists of major industry influencers found in the study.

Table of Contents
Product Code: D86A

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Research Scope: RNA Therapies Redefining the Healthcare Landscape
  • 1.2. Analysis Framework: Frost & Sullivan's Core Value
  • 1.3. Research Methodology: Five Steps Towards Success
  • 1.4. Key Findings

2.0. RNA THERAPIES: INDUSTRY OVERVIEW

  • 2.1. RNA is the Rising Star of Transformative Therapy Platforms
  • 2.2. Industry Accelerators and Challenges
  • 2.3. RNA Delivery: Technology Segmentation
  • 2.4. RNA Therapies: Technology Segmentation
  • 2.5. Molecular Insights Across RNA Therapy

3.0. TECHNOLOGY TRENDS & CLINICAL PIPELINE

  • 3.1. Alternative Splicing Induced by SSO Therapies
  • 3.2. Clinical Pipeline Analysis for SSO Therapies for SMA and DMD
  • 3.3. Post-transcriptional Modifications by ASO
  • 3.4. Clinical Pipeline Overview for ASO Therapies
  • 3.5. Emerging Clinical Pipeline for ASO Therapies
  • 3.6. Early Phase ASO Therapies
  • 3.7. Inhibition of Ligand Binding by Aptamer
  • 3.8. Clinical Pipeline Analysis for Aptamer Therapies
  • 3.9. Landmark Year for RNA Interference Therapy Platform
  • 3.10. Clinical Analysis of RNA Interference Therapeutics
  • 3.11. Overview of the Emerging Landscape for mRNA Therapies
  • 3.12. Clinical Pipeline Analysis of mRNA Therapies
  • 3.13. saRNA: The Rising Participant in RNA-based Therapies

4.0. OVERVIEW OF THE PATENT LANDSCAPE

  • 4.1. Patenting Trends for ASO Technologies
  • 4.2. Patenting Trends for RNAi Platforms
  • 4.3. Patenting Trends for mRNA Technologies

5.0. INNOVATION PROFILES

  • 5.1. Targeted RNAi Technology for Enhanced Disease Management
  • 5.2. Enabling Targeted Delivery of RNAi Therapeutics
  • 5.3. Developing Stable and Non-immunogenic mRNA Therapies
  • 5.4. Fueling Novel RNA Therapy and Delivery Platforms
  • 5.5. Enabling Potent Antisense Therapeutics

6.0. FUTURE PERSPECTIVES

  • 6.1. RNA Platforms likely to Transform the Future of Health & Wellness
  • 6.2. Navigating Through The Future Landscape for RNA Technologies

7.0. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

  • 7.1. Growth Opportunity 1: ASO Therapies
  • 7.2. Growth Opportunity 2: RNAi Therapies
  • 7.3. Growth Opportunity 3: mRNA Therapies
  • 7.4. Strategic Imperatives for Success and Growth

8.0. KEY INDUSTRY INFLUENCERS

  • 8.1. Industry Interactions
  • 8.1. Industry Interactions (continued)
Back to Top